Enabling Access to Osteoporosis Treatment with the Biosimilars Movement

Osteoporosis affects over 200 million women worldwide.¹ Learn how biosimilars can help expand access to potentially more affordable, effective treatments for patients but are also critical to helping build a resilient healthcare system.

As people around the world live longer,² we believe that women and men should be empowered to live a higher quality of life, without the burden of dependency and disability.

“We live in a time in which women’s health is often overlooked while essential health services are crumbling under the weight of aging populations and half of the world’s population lacks access to the medicines and resources they need,” says Joe Azzinaro, Vice President and head of Organon’s biosimilar business.

With osteoporosis now recognized as a major public health issue affecting 200 million women,¹ enabling better access to treatments is key. People living with osteoporosis can face potentially life-limiting conditions such as risk of fractures, chronic pain, reduced mobility, disability and a profound loss of independence.³

We play a vital role in helping women and men gain access to effective treatments for osteoporosis by investing in biosimilars, which are medicines that have been developed to be highly similar to an already approved biologic treatment.⁴

Biosimilar medicines stimulate competition in the market which has the potential to reduce the price of medicines, allowing more patients to be treated with these therapies and in turn, generates cost savings within the healthcare system.⁵

“At this critical moment, the value of biosimilars could not be clearer; they allow us to expand access to potentially more affordable treatment options. At Organon, we are committed to supporting women to live healthier lives, and as a result, enrich the lives of the families and communities they belong to”, continues Joe.  

Central to delivering on this mission is working with key players at every level, from biosimilar manufacturers, payers, and governments to the medical community. We are proud to contribute as active members of industry associations around the world, including the Biosimilars Forum in the US, Biosimilars Canada and supporters of the Mabel Fund in Europe that leads research around the biosimilar market dynamics.

Along with like-minded partners and stakeholders, we work to instill confidence in biosimilars and support their uptake around the world. Together, we play a vital role in creating a world where healthcare ecosystems stay resilient enough to provide care now, and for generations to come.

¹ Liang, H., Chen, S., Shi, M. et al. Global epidemiology and burden of osteoporosis among postmenopausal women: insights from the Global Burden of Disease Study 2021. npj Aging 11, 78 (2025). https://doi.org/10.1038/s41514-025-00269-2

² United Nations, Ageing populations: We are living longer lives, but are we healthier?, 2021 Available: undesa_pd_2021_technical_paper_no.2_healthy_life_expectancy.pdf [last accessed: December 2025]

³ Das C, Das PP, Kambhampati SBS. Sarcopenia and Osteoporosis. Indian J Orthop. 2023;57(Suppl 1):33-41. Published 2023 Nov 19. doi:10.1007/s43465-023-01022-1

⁴ Biosimilar basics for patients. US Food and Drug Administration. March 21, 2023. Accessed April 12, 2023. https://www.fda.gov/drugs/biosimilars/biosimilar-basics-patients

⁵ Aitken M, Mugele D, Newton M, Rodríguez I, Vázquez M. Spotlight on Biosimilars. IQVIA Institute for Human Data Science. June 2021. Accessed November 5, 2025. https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/spotlight-on-biosimilars